|Day Low/High||46.11 / 46.94|
|52 Wk Low/High||37.59 / 57.81|
TheStreet highlights 3 stocks pushing the drugs industry lower today.
The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
Trade-Ideas LLC identified Mylan (MYL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
The buyer agrees to asset sales to allay the antitrust concerns of Brussels regulators.
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
The French bank's advisory business plans to increase its market share in the U.S.
The transaction follows a Houlihan Lokey-run sale process for the drugmaker's private-label nutraceuticals unit that was started after Mylan NV's takeover attempt was rebuffed.
With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.
After companies like Valeant Pharmaceuticals and Martin Shkreli's Turing Pharmaceuticals have come under heavy fire for buying medicines and then jacking up their prices, Mylan may be...
Stocks with insider trader activity include MYL, PKD and MDVN
Mylan (MYL) stock is up in late-afternoon trading on Monday after its breast cancer treatment proved comparable to a more expensive medicine by a competitor.
HERITAGE Study Shows Comparable Efficacy, Safety and Immunogenicity to Branded Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients
Goldman Sachs put together a list of 17 stocks that looked 'cheap' when considering their debt-adjusted cash flow. Here are five names that also had positive-looking charts and indicators.
Are you a value investor? Goldman Sachs says you may want to consider adding a company's debt-adjusted cash flow when evaluating stocks.